Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Novozymes for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications.
Tim Zeppenfeld, business development manager of Gene Bridges, said: “We are very pleased to add Novozymes to the list of major industrial biotechnology companies using Red/ET. Recombineering is the technology of choice in metabolic engineering and is used worldwide in industry and academia.”